KIORA PHARMACEUTICALS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
KIORA PHARMACEUTICALS, INC. (KPRX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $3.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-25
- KIORA PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $3.70M.
- KIORA PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$19.90M, a 685.29% decline from fiscal 2023.
- KIORA PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $3.40M, a 161.54% increase from fiscal 2022.
- KIORA PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $1.30M, a 56.67% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $3.70M 10-K · filed 2026-03-25 | |
| 2024-12-31 | -$19.90M 10-K · filed 2026-03-25 | |
| 2023-12-31 | $3.40M 10-K · filed 2025-03-25 | |
| 2022-12-31 | $1.30M 10-K · filed 2024-03-25 | |
| 2021-12-31 | $3.00M 10-K · filed 2023-03-23 | $3.31M 10-K · filed 2022-04-15 |
| 2020-12-31 | -$958.00K 10-K/A · filed 2022-07-07 | |
| 2019-12-31 | $2.62M 10-K · filed 2021-03-25 | |
| 2018-12-31 | -$416.00K 10-K · filed 2020-03-04 | $416.00K 10-K · filed 2019-03-01 |
| 2017-12-31 | $6.80M 10-K · filed 2019-03-01 | |
| 2016-12-31 | $4.81M 10-K · filed 2018-03-02 | $4.81M 10-K · filed 2017-02-23 |
| 2015-12-31 | $2.48M 10-K · filed 2017-02-23 | |
| 2014-12-31 | $1.31M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |